Department:Toxicologic Experimental and Molecular Pathology
University:Louisiana State University Baton Rouge, LA
Toxicologic Pathologist. Specialist in Biomarker Implementation. Experienced Professional in Molecular and Discovery Pathology. Protocol Development and Validation. Problem Solving. Manager of R&D Scientists. Characterization of Models of Human Diseases. Pharmacology Studies. Regulatory Toxicology.
Position in Toxicologic Experimental and Molecular Pathology and Biomarkers
University:Federal University of the State of Rio de Janeiro
Claudia AF Aiub currently works in the lines of Toxicology and natural products synthesis, Genetics and Molecular Mutagenesis with research cooperation in the Oswaldo Cruz Foundation (FIOCRUZ) research at the National Institute of Quality Control in Health (INCQS) and the University of State of Rio de Janeiro (UERJ). She is an adjunct professor of 40h DE Department of Genetics and Molecular Biology UNIRIO. Has Postdoc in Molecular Genetics (University of Salzburg, Austria) and Doctor of Science in the field of Nuclear Biosciences (UERJ). His Masters, held at the Pontifical University of Rio Grande do Sul was PUCRS in Biosciences, in Physiology and Biochemistry Recent Groups. Have expertise in Toxicology, course held PUCRS. He joined the Undergraduate course in Biological Sciences at PUC, completing it in 1995, having received throughout their period of scientific initiation scholarships, all in the field of genetic toxicology.
University:Global Clinical Research Scholar at the Harvard Medical School
Country:United States Army Medical Research Directorate Africa- Nigeria
Dr. Afoke Kokogho is a Clinical Research Physician with the United States Army Medical Research Directorate Africa- Nigeria with advanced expertise and broad experience with infectious disease clinical research. He is currently a Global Clinical Research Scholar at the Harvard Medical School, pursuing a fellowship that provides further advanced training in clinical trials and epidemiology. He is focused on the conduct, design, and implementation of clinical trials, epidemiological studies, biostatistics, bio-surveillance, and biosecurity in the context of emerging infectious diseases across West Africa. He holds a master's in public health from the University of Roehampton London and a degree in Medicine and Surgery from Delta state university Nigeria, amongst other training and certifications. As principal investigator and associate investigator, he successfully executed a number of multi-country vaccine trials viz., Ebola vaccine trials with pharmaceuticals like GSK and Johnson & Johnson during and after the last Ebola outbreak in Nigeria. He has also led and participated in the execution of a number of NIH (The National Institutes of Health) approved cohort studies involving HIV and Key populations geared towards developing an effective HIV vaccine, which yielded excellent publications in Peer-reviewed journals.
• Successful Completion as the Principal investigator of the RV368 Trust Study (cohort), which focuses on HIV and STI prevalence, incidence and risk behaviors among MSM in Nigeria and impact of providing HIV medical and prevention services to Nigerian MSM at a Trusted Community Centre. This study was conducted over a period of five (5) years. • Exceeded enrolment targets and full implementation of the RV 429 protocol the successful implementation of the GSK sponsored multi-country Ebola vaccine trials - RV 429 (Safety And Immunogenicity Study Of GSK Biologicals’ Investigational Recombinant Chimpanzee Adenovirus Type 3-Vectored Ebola Zaire Vaccine (Chad3-EBO-Z) (GSK33901107A) In Adults In Africa) Protocol as an Associate investigator and study coordinator. With an Award of a Top performing site. • As principal Investigator for the Nigerian site, my team successfully implemented the Jansen and Jansen sponsored multi-country Ebola vaccine trial -RV 456 (A Randomized, Observer-blind, Placebo-controlled, Two-part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo). My team laid the groundwork for developing an effective recruitment strategy that has led to a sustained retention rate of above 95% since initiation of vaccine trials across all studies at the Nigerian site. Based on very high expectations and the need to deliver quality research, my team developed a site quality plan used for ensuring strict compliance to good clinical practice, which has been used as templates across other research sites. In addition, I have successfully managed staffing, supported compliance with regulatory bodies and executed study budgets precisely on projects that have led to publication of papers in peer reviewed journals. Assembling a strong team with a realistic plan, time and budget has been instrumental to my success as an investigator.
Focused on bio-surveillance, biosecurity and clinical trials in the context of emerging infectious diseases My core competency areas include conducting epidemiological studies, biostatistics, design and implementation of clinical trials
Dr Tarek Mohamed Kamal Mohamed Metawie, Professor of Biochemistry, Faculty of Pharmacy, Cairo University. Egyptian, date of birth 6/3/1955. Ph.D. in Pharmaceutical Sciences, 1984; M.Sc. in Pharmaceutical Sciences, 1979; B.Sc. in Pharmaceutical Sciences, Faculty of Pharmacy, Cairo University, 1976. Professional experience: Instructor; 1976, Lecturer Assistant; 1980, Lecturer, 1984; Assistant Professor, 1989; Professor,1994; Head of the Department of Biochemistry, Faculty of Pharmacy, Cairo:- 2008-2014.
Education • Academic Degrees PhD Ph.D. in Pharmaceutical Sciences (Biochemistry), 1984, Cairo University Master M.Sc. in Pharmaceutical Sciences (Biochemistry), 1979, Cairo University Bachelor B.Sc. in Pharmaceutical Sciences, 1976, Faculty of Pharmacy, Cairo University • Research interest Biochemistry Molecular Biology and Genetics Molecular Neurobiology Biochemical Toxicology Nutrition Cancer Teaching Course Title Undergraduate Courses (General Program) 701 Biochemistry I 702 Biochemistry II 703 Clinical Chemistry and Molecular Biology Undergraduate Courses (Clinical Program) PB 401 Biochemistry-1 PB 502 Biochemistry-2 Postgraduate Courses
• Shared in teaching Biochemistry courses for Pharmacy postgraduate students (Master and Diploma degrees) in Faculty of Pharmacy, Cairo University. Master: 2701 Biochemistry-1 Diploma: 1701 and 1702 • Shared in teaching Biochemistry courses for Pharmacy postgraduate students in Faculty of Pharmacy, Ain Shams University. • Shared in teaching Biochemistry courses for Pharmacy postgraduate students in Faculty of Pharmacy, Beni-Suef University. • Shared in development and upgrading of postgraduate curricula and courses (Master and Diploma) of Pharmaceutical Sciences (Biochemistry), Faculty of Pharmacy, Cairo University.
Biochemistry, Molecular Biology and Genetics, Molecular Neurobiology, Biochemical Toxicolog, Nutrition, Cancer
Ufuk MERCAN YÜCEL presently working as Assistant Professor in pharmacology and Toxicology Department at University of Van Yüzüncü Y?l, Faculty of Veterinary Medicine. She is received her PhD degree in Pharmacology and Toxicology at University of Van Yüzüncü Y?l (Van-Turkey). She conducted postdoctoral research on neurotoxicology.
She is supervisor on three master's degrees and two PhD students. She 25 national and international papers published. Presently, her handling 9 projects concentrating mainly on Drug interaction, Acut toxicity, reproductive toxicology, heavy metals, alpha toxins. She participated in several international conferences and national congress. Research interest: Pharmacology, Clinical Pharmacology; Experimental Pharmacology and Clinical Trials; Toxicology; Clinical Toxicology
University:Mexican University: Universidad Michoacana de San Nicolas de Hidalgo
Alondra Alelie Cortés Téllez currently works at the Faculty of Pharm Biology Chemistry, Universidad Michoacana de San Nicolás de Hidalgo. Alondra does research in Biochemistry, Pharmacology and Environmental Chemistry.
Their current project is 'Adaptation to Cd-resistant strain of Dictyosphaerium chlorelloides to abiotic factores and interaction of toxic metals'. Ph.D student Date of production: Degree: December 3, 2012 Chemical-Pharmacobiology Educational level: Bachelor’s degree Date of production: Degree: March 17, 2015 Master in Biological Sciences Educational level:
Master’s degree Date of production: Degree: Institution: March 5, 2020 PhD in Biological Sciences, Environmental Toxicology Mexican University: Universidad Michoacana de San Nicolas de Hidalgo Educational Level: Doctorate’s degree Date: Research Institution: Date: Research: Institution: 01/mar/2017 Academic Complutense De Madrid University 01/abr/2014 Academic Complutense De Madrid University End Date: Nombre de estancia: End Date: Nombre de estancia: Research Stay in Environmental Toxicology Departmen
Head of the Venoms and Toxins laboratory
Department:Immunotherapy and molecular biology of antibodies
University:Institut Pasteur, Casablanca, Morocco
Dr. Naoual Oukkache works as Researcher at Pasteur Institute in Morocco since 2006. Currently, she is a responsible of the Venoms and Toxins laboratory at Pasteur Institute of Morroco. She has built a solid research on immunotherapy and molecular biology of antibodies. In addition to being an active scientist with several scientific projects, she is the manager of Intellectual Property valuation procedures and Privacy search results. She published more than 20 scientific articles in different peer reviewed international journals and contributed to numerous conferences.
Her specific areas of expertise include characterization of snake and scorpion venoms, venomics and antivenomics, therapeutics molecules from venoms and improvement of immunotherapy. She did internships with several international Institutes “Leaders” in the field of venom studies and the anti-venom design: - 2003 -2005: Characterization of venoms by proteomic approaches – Protein engineering laboratory Faculty of Medicine of Marseille, France. Electrophoresis, gel filtration chromatography, HPLC, MALDI-TOF-MS, ELISA, radioimmunoassay, toxicity assay in mice with different routes (ICV, IP and IV), Edman protein sequencing. - 2007 -2008: Herpetology and Arachnid laboratories – Butantan Institute in Sao Paolo, Brazil.
Animal venoms production, immunobioassays, venom extraction, antigen preparation, liophilization, standardization tests and process control of the venoms, Characterization of the venoms (protein content, Eletrophoresis SDS-PAGE, LD50, ED50), physiopatological studies. - 2007 -2008: Venoms – storage and quality control – Butantan Institute. - 2007 -2008: Hyperimmune sera production in GMP environment – Butantan Institute. Antigen preparation, immunization of horses, plasmapheresis, downstream processing (plasma to F(ab’)2), pre-clinical studies, neutralization studies of the scorpion and snake antivenoms. - 2010: Venoms and antivenoms studies – Laboratory of venoms and toxins, Institute of Biotechnology, Cuernavaca, Mexico.
Preclinical studies of an scorpion antivenom, Development of an ELISA for the determination of venom and antivenom (F(ab’)2) in the blood of patients envenomed by scorpion venom. - 2011: Antibodies engineering – Venoms and toxins Lab, Pasteur Institute of Tunis, Tunisia. Study of cross-reactions between the venoms of the deadliest scorpions in the MATI region (Morocco, Algeria, Tunisia and Iran). - 2012: Proteomics Lab at Monash University of Kula Lumpur, Malaysia. Characterization of the venoms of the most dangerous Moroccan scorpion and snake species.
Pharmacological studies of two Moroccan scorpion venoms. Preclinical studies of an experimental polyvalent scorpion antivenom. - 2016: Peptide and protein drug discovery - Atheris SA – Geneva, Switzerland. The purification of new molecules from Moroccan scorpion venoms that could have a therapeutic use, their characterization by mass electrospray spectrometry coupled to Masslynx analysis, preliminary venom gland transcriptomic studies”. - 2018: Technology Transfer Training on dosing of venom and antivenom in the blood of envenomed patients. Institut Vivotecnia-Research Organisation (Preclinical CRO), Madrid, Spain. - 2019: Training on the study of anti-cancer activity of cobra Naja haje venom. Molecular Oncology Laboratory - Institut Pasteur of Rome
Venoms and Toxins laboratory, immunotherapy and molecular biology of antibodies